Autopsy report · NCT01440595

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

“Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 5 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 3 years 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Hepatitis C, Chronic

Interventions

Grazoprevir; Placebo to Grazoprevir; Peginterferon alfa-2b (Peg-IFN); Ribavirin (RBV)

Participants

5

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.